Manhattan Eye, Ear & Throat Hospital
New York, 10021, United States
NCT Number: NCT00211419
The purpose of this study is to evaluate the safety of combining juxtasclerally administered anecortave acetate 15 mg with triamcinolone acetate 4 mg administered intravitreally following photodynamic therapy with verteporfin for the treatment of exudative age-related macular degeneration (AMD).
Looking for future studies?
Notify Me50 year and older
All sexes
Interventional
Phase 1
New York, 10021, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Manhattan Eye, Ear & Throat Hospital
Other
Pilot Study of the Combination of Anecortave Acetate 15mg Delivered by Posterior Juxtascleral Injection and Triamcinolone Acetonide 4mg Delivered by Intravitreal Injection for the Treatment of Exudative Age-Related Macular Degeneration (AMD)
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01024998
Age-Related Maculopathies, Age-Related Maculopathy
Baltimore, Maryland, United States
View Trial DetailsNCT00058994
Eye Diseases, Macular Degeneration
Fort Worth, Texas, United States
View Trial DetailsNCT00051129
Age-Related Maculopathies, Age-Related Maculopathy
View Trial DetailsNCT00417846
Amino Acid Metabolism, Inborn Errors, Brain Diseases
Beverly Hills, California, United States
View Trial Details